The idea of the facility was prompted by the company's partnership with Stevenage Bioscience Catalyst, the U.K. government, and the Stevenage Borough Council. GSK plans to sell 33 acres of land in the area to raise 400 million pounds sterling ($551 million U.S.); the land purchaser would develop the new campus, it said. The facility could create up to 5,000 life science research and development jobs over the next five to 10 years.

The Cell and Gene Therapy Catapult and Stevenage Bioscience Catalyst are both already on the site and have attracted a number of successful start-ups which collectively have raised around 1.6 billion pounds ($2.2 billion) of funding, according to the firm.

GSK plans to choose a development partner later this year and to begin planning for the facility in 2022, according to the firm.

Sanofi, GSK initiate phase III trial of COVID-19 vaccine
Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine...

FDA issues EUA for GSK-Vir COVID-19 mAb treatment
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab...

EMA gives positive nod to GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology today announced that the European Medicines Agency's (EMA) Committee for Human Medicinal Products has issued...

Medicago, GSK tout positive COVID-19 vaccine results
Medicago and GlaxoSmithKline (GSK) announced positive interim phase II results for their adjuvanted COVID-19 vaccine candidate.

Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all...